Clinical trial NCT02926482 - References

Opioid-use Disorder — Intervention to Expand Opioid Use Disorder Treatment Pharmacotherapy Prescribers

Citation(s)

•   Berglund M
  A better widget? Three lessons for improving addiction treatment from a meta-analytical study. Addiction. 2005 Jun;100(6):742-50.
•   Burke WW, Litwin GH
  A causal model of organizational performance and change. In: Burke WW, Lake DG, Paine JW, eds. Organizational change: A comprehensive reader. San Francisco, CA: Jossey-Bass; 2009:273-299.
•   Centers for Disease Control and Prevention (CDC)
  Vital Signs: Opioid painkiller prescribing. 2014.
•   Chen LH, Hedegaard H, Warner M
  Drug-poisoning Deaths Involving Opioid Analgesics: United States, 1999-2011. NCHS Data Brief. 2014 Sep;(166):1-8.
•   Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group
  Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003 Sep 4;349(10):949-58.
•   Goldstein MG, Niaura R, Willey C, Kazura A, Rakowski W, DePue J, Park E
  An academic detailing intervention to disseminate physician-delivered smoking cessation counseling: smoking cessation outcomes of the Physicians Counseling Smokers Project. Prev Med. 2003 Feb;36(2):185-96.
•   Hoffman KA, Ford JH 2nd, Choi D, Gustafson DH, McCarty D
  Replication and sustainability of improved access and retention within the Network for the Improvement of Addiction Treatment. Drug Alcohol Depend. 2008 Nov 1;98(1-2):63-9. doi: 10.1016/j.drugalcdep.2008.04.016. Epub 2008 Jun 18.
•   Horgan CM, Reif S, Hodgkin D, Garnick DW, Merrick EL
  Availability of addiction medications in private health plans. J Subst Abuse Treat. 2008 Mar;34(2):147-56. Epub 2007 May 17.
•   Imai K, Keele L, Tingley D
  A general approach to causal mediation analysis. Psychol Methods. 2010 Dec;15(4):309-34. doi: 10.1037/a0020761.
•   Institute of Medicine (US) Committee on Quality of Health Care in America
  Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC): National Academies Press (US); 2001.
•   Jones CM, Campopiano M, Baldwin G, McCance-Katz E
  National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health. 2015 Aug;105(8):e55-63. doi: 10.2105/AJPH.2015.302664. Epub 2015 Jun 11.
•   Klein KJ, Conn AB, Sorra JS
  Implementing computerized technology: an organizational analysis. J Appl Psychol. 2001 Oct;86(5):811-24.
•   Knudsen HK, Abraham AJ, Oser CB
  Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure. Eval Program Plann. 2011 Nov;34(4):375-81. doi: 10.1016/j.evalprogplan.2011.02.004. Epub 2011 Mar 2.
•   Knudsen HK, Abraham AJ, Roman PM
  Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011 Mar;5(1):21-7. doi: 10.1097/ADM.0b013e3181d41ddb.
•   MacKinnon DP
  Introduction to statistical mediation analysis. New York, NY: Lawrence Erlbaum Associates; 2008.
•   Mattick RP, Breen C, Kimber J, Davoli M
  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014 Feb 6;(2):CD002207. doi: 10.1002/14651858.CD002207.pub4. Review.
•   McCarty D, Gustafson DH, Wisdom JP, Ford J, Choi D, Molfenter T, Capoccia V, Cotter F
  The Network for the Improvement of Addiction Treatment (NIATx): enhancing access and retention. Drug Alcohol Depend. 2007 May 11;88(2-3):138-45. Epub 2006 Nov 28.
•   Molfenter T, Kim JS, Quanbeck A, Patel-Porter T, Starr S, McCarty D
  Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial. Implement Sci. 2013 May 10;8:50. doi: 10.1186/1748-5908-8-50.
•   Molfenter T, Sherbeck C, Zehner M, Starr S
  Buprenorphine Prescribing Availability in a Sample of Ohio Specialty Treatment Organizations. J Addict Behav Ther Rehabil. 2015;4(2). pii: 1000140.
•   Raudenbush SW, Liu X
  Statistical power and optimal design for multisite randomized trials. Psychol Methods. 2000 Jun;5(2):199-213.
•   Schroeder SA
  An agenda to combat substance abuse. Health Aff (Millwood). 2005 Jul-Aug;24(4):1005-13.
•   Singer JD, Willett JB
  Applied longitudinal data analysis: modeling change and event occurrence. New York, NY: Oxford University Press; 2003.
•   Soumerai SB, Avorn J
  Principles of educational outreach ('academic detailing') to improve clinical decision making. JAMA. 1990 Jan 26;263(4):549-56.
•   Stein BD, Gordon AJ, Dick AW, Burns RM, Pacula RL, Farmer CM, Leslie DL, Sorbero M
  Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat. 2015 Jan;48(1):104-11. doi: 10.1016/j.jsat.2014.07.010. Epub 2014 Aug 2.
•   Substance Abuse and Mental Health Services Administration (SAMHSA)
  The N-SSATS Report: Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011. Rockville, MD: Center for Behavioral Health Statistics and Quality;2013.
•   Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality
  Treatment Episode Data Set (TEDS): 2002-2012. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse Mental Health Services Administration;2014.
•   Tremblay MA, Blanchard CM, Taylor S, Pelletier LG, Villeneuve M
  Work Extrinsic and Intrinsic Motivation Scale: Its value for organizational psychology research. Canadian Journal of Behavioural Science/Revue canadienne des sciences du comportement. 2009;41(4):213-226.
•   Warner M, Hedegaard H, Chen L
  Trends in drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999-2012. NCHS Health E-Stat. 2014
•   Williams ES, Konrad TR, Linzer M, McMurray J, Pathman DE, Gerrity M, Schwartz MD, Scheckler WE, Van Kirk J, Rhodes E, Douglas J
  Refining the measurement of physician job satisfaction: results from the Physician Worklife Survey. SGIM Career Satisfaction Study Group. Society of General Internal Medicine. Med Care. 1999 Nov;37(11):1140-54.

Test of a Workforce Development Intervention to Expand Buprenorphine Prescribers

Details for clinical trial NCT02926482